Rhythm Pharmaceuticals (RYTM) Form 4: Insider Sells 1,500 Shares via 10b5-1
Rhea-AI Filing Summary
Christopher Paul German, Corporate Controller & CAO of Rhythm Pharmaceuticals (RYTM), reported buy and sell transactions on 08/12/2025. The Form 4 shows acquisitions of 1,000 shares at $17.97 and 500 shares at $49.23, and a sale of 1,500 shares at $95. Following these transactions, the reporting person beneficially owned 922 shares. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted March 11, 2025. The filing also discloses outstanding stock options: 1,000 options (exercise price $17.97) exercisable beginning 04/03/2033 and 500 options (exercise price $49.23) exercisable beginning 02/15/2034, with detailed vesting schedules provided.
Positive
- Sale executed under a Rule 10b5-1 trading plan, indicating a pre-established plan intended to reduce insider trading risk
- Detailed option grant and vesting schedules disclosed, improving transparency around future potential exercises
Negative
- Net beneficial ownership decreased to 922 shares after the sale of 1,500 shares at $95
- Reported transactions include sales and purchases on the same date, which may complicate simple interpretations of insider sentiment
Insights
TL;DR: Insider executed both purchases and a plan sale; net beneficial ownership decreased to 922 shares after a Rule 10b5-1 sale.
The transactions are a mix of market purchases and a pre-established sale under a 10b5-1 plan. The sale of 1,500 shares at $95 reduced reported holdings to 922 shares despite contemporaneous acquisitions at lower prices. The filing separately details outstanding stock options with specific grant dates, exercise prices, and vesting schedules, which are relevant for potential future insider-aligned activity or dilution.
TL;DR: Use of a documented 10b5-1 plan and clear option disclosures reflect compliance with insider trading rules.
The Form 4 clearly states the sale was made pursuant to a 10b5-1 trading plan adopted March 11, 2025, which provides an affirmative defense to allegations of trading on material nonpublic information. The filing includes explicit option grant and vesting details, aiding transparency regarding the reporting person’s potential future exercises and timing of insider liquidity.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Options (Right to Buy) | 1,000 | $0.00 | -- |
| Exercise | Stock Options (Right to Buy) | 500 | $0.00 | -- |
| Exercise | Common Stock | 1,000 | $17.97 | $18K |
| Exercise | Common Stock | 500 | $49.23 | $25K |
| Sale | Common Stock | 1,500 | $95.00 | $143K |
Footnotes (1)
- The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 11, 2025. The stock options were granted on April 4, 2023. The options vest and become exercisable as to 25% of the total shares on March 20, 2024 and, thereafter, as to the remaining 75% of the total shares in twelve equal quarterly installments of 6.25% beginning June 20, 2024 and ending March 20, 2027, subject to the Reporting Person's continued service on each such vesting date. The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
